P500 Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
المؤلفون الرئيسيون: | Cohen, R, Bhayat, F, Blake, A, Travis, S |
---|---|
التنسيق: | Conference item |
منشور في: |
Oxford University Press
2019
|
مواد مشابهة
-
Post-marketing experience of vedolizumab: Pneumonia and other respiratory tract infections
حسب: Bhayat, F, وآخرون
منشور في: (2017) -
Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
حسب: Bhayat, F, وآخرون
منشور في: (2017) -
Post-marketing safety experience of vedolizumab in older patients with inflammatory bowel disease
حسب: Travis, S, وآخرون
منشور في: (2018) -
The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
حسب: Cohen, R, وآخرون
منشور في: (2019) -
Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data
حسب: Card, T, وآخرون
منشور في: (2019)